Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

References

• Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2012;30(20):2475–2482.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Knauf W, Dingeldein G, Schlag R, et al. First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. Eur J Haematol. 2020;105(2):116–125.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2):265.
   PubMed Web of Science ®Google Scholar
• Nishida H, Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. J Oncol. 2019;2019:6084012.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102(10):1767–1775.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1503–1512.
   PubMed Web of Science ®Google Scholar
• Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011;17(23):7313–7323.
   PubMed Web of Science ®Google Scholar
• Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China continuation study. J Hematol Oncol. 2017;10(1):137.
   PubMedGoogle Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253–264.
   PubMed Web of Science ®Google Scholar
• Varga G, Nagy Z, Demeter J, et al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the hungarian ixazomib named patient program. Pathol Oncol Res. 2019;25(4):1615–1620.
   PubMed Web of Science ®Google Scholar
• Ding K, Yu H, Shao YY, et al. Real-world data on the efficacy and safety of ixazomib-based therapy in multiple myeloma: a single-center study in China. Cancer Manag Res. 2020;12:8935–8941.
   PubMed Web of Science ®Google Scholar
• Sokol J, Guman T, Chudej J, et al. Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma. Ann Hematol. 2022;101(1):81–89.
   PubMed Web of Science ®Google Scholar
• Takakuwa T, Yamamura R, Ohta K, et al. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: a multicenter retrospective analysis. Eur J Haematol. 2021;106(4):555–562.
   PubMed Web of Science ®Google Scholar
• Ziff M, Lawson G, De-Silva D, et al. Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leuk Lymphoma. 2021;62(5):1243–1246.
   PubMed Web of Science ®Google Scholar
• Maouche N, Kishore B, Jenner MW, et al. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma. 2021;62(6):1396–1404.
   PubMed Web of Science ®Google Scholar
• Terpos E, Ramasamy K, Maouche N, et al. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049–1061.
   PubMed Web of Science ®Google Scholar
• Spencer A, Samoilova O, Chng WJ, et al. Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial. EJHaem. 2022;3(4):1241–1251.
   PubMedGoogle Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Terpos E, Maouche N, Minarik J, et al. “Real world” data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: a combined study from the Greek, Czech and UK databases. Blood. 2017;130:3087.
   Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–1980.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5321.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu A, Li L. The MODIFY study protocol: an open-label, single-arm, multicenter, prospective pragmatic study of Ixazomib-based triple-drug therapy in Chinese patients with multiple myeloma. Adv Ther. 2023;40(2):705–717.
   PubMed Web of Science ®Google Scholar
• Iida S, Izumi T, Komeno T, et al. A phase 2, open-label, multicenter study of Ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. Int J Clin Oncol. 2022;27(1):224–233.
   PubMed Web of Science ®Google Scholar
• Minarik J, Radocha J, Jungova A, et al. Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy. Cancers (Basel). 2022;14(20):5165.
   PubMed Web of Science ®Google Scholar
• Li J, Zhuang J, Wei Z, et al. Real-world data on the efficacy and safety of ixazomib based therapy in multiple myeloma: an observational study from China. Clin Lymphoma Myeloma Leuk. 2019;19(10):e265.
   Web of Science ®Google Scholar